These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 17641799)

  • 1. Molecular changes in superficial bladder cancer.
    Vrabie CD; Petrescu A; Waller M
    Rom J Morphol Embryol; 2007; 48(2):131-8. PubMed ID: 17641799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular alterations associated with bladder cancer initiation and progression.
    Cordon-Cardo C
    Scand J Urol Nephrol Suppl; 2008 Sep; (218):154-65. PubMed ID: 18815930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cooperative effects of p53 and pRB alterations in primary superficial bladder tumors.
    Cordon-Cardo C; Zhang ZF; Dalbagni G; Drobnjak M; Charytonowicz E; Hu SX; Xu HJ; Reuter VE; Benedict WF
    Cancer Res; 1997 Apr; 57(7):1217-21. PubMed ID: 9102201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma.
    Shariat SF; Ashfaq R; Sagalowsky AI; Lotan Y
    J Urol; 2007 Feb; 177(2):481-7; discussion 487. PubMed ID: 17222615
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacodynamics of doxorubicin in human bladder tumors.
    Gan Y; Wientjes MG; Badalament RA; Au JL
    Clin Cancer Res; 1996 Aug; 2(8):1275-83. PubMed ID: 9816297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p53 and RB expression predict progression in T1 bladder cancer.
    Grossman HB; Liebert M; Antelo M; Dinney CP; Hu SX; Palmer JL; Benedict WF
    Clin Cancer Res; 1998 Apr; 4(4):829-34. PubMed ID: 9563875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proliferative status is a risk index for recurrence in primary superficial (pTa/T1) low-grade urothelial bladder carcinoma.
    Su JS; Arima K; Hasegawa M; Franco OE; Yanagawa M; Sugimura Y; Kawamura J
    Hinyokika Kiyo; 2003 Nov; 49(11):649-58. PubMed ID: 14719452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proliferative activity is the most significant predictor of recurrence in noninvasive papillary urothelial neoplasms of low malignant potential and grade 1 papillary carcinomas of the bladder.
    Pich A; Chiusa L; Formiconi A; Galliano D; Bortolin P; Comino A; Navone R
    Cancer; 2002 Aug; 95(4):784-90. PubMed ID: 12209722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The predictive value of muscularis mucosae invasion and p53 over expression on progression of stage T1 bladder carcinoma.
    Bernardini S; Billerey C; Martin M; Adessi GL; Wallerand H; Bittard H
    J Urol; 2001 Jan; 165(1):42-6; discussion 46. PubMed ID: 11125360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Superficial bladder cancer: part 1. Update on etiology, classification and natural history.
    Josephson DY; Pasin E; Stein JP
    Expert Rev Anticancer Ther; 2006 Dec; 6(12):1723-34. PubMed ID: 17181486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BCL-2, TP53 and BAX protein expression in superficial urothelial bladder carcinoma.
    Gonzalez-Campora R; Davalos-Casanova G; Beato-Moreno A; Garcia-Escudero A; Pareja Megia MJ; Montironi R; Lopez-Beltran A
    Cancer Lett; 2007 Jun; 250(2):292-9. PubMed ID: 17126995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The frequency of hydronephrosis at initial diagnosis and its effect on recurrence and progression in patients with superficial bladder cancer.
    Divrik RT; Sahin A; Altok M; Unlü N; Zorlu F
    J Urol; 2007 Sep; 178(3 Pt 1):802-6; discussion 806. PubMed ID: 17632171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidermal growth factor receptor, MUC-1 and MUC-2 in bladder cancer.
    Cardillo MR; Castagna G; Memeo L; De Bernardinis E; Di Silverio F
    J Exp Clin Cancer Res; 2000 Jun; 19(2):225-33. PubMed ID: 10965823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Immunohistochemical examination for p53 overexpression in Ta bladder cancer with disease progression].
    Tsukamoto T; Fujioka T; Nakano H; Takanashi K
    Hinyokika Kiyo; 1996 May; 42(5):347-9. PubMed ID: 8752536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of polysomy 17 in transitional cell carcinoma of the bladder: immunohistochemical study of HER2/neu expression and fish analysis of c-erbB-2 gene and chromosome 17.
    Simonetti S; Russo R; Ciancia G; Altieri V; De Rosa G; Insabato L
    Int J Surg Pathol; 2009 Jun; 17(3):198-205. PubMed ID: 19443884
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Endoscopic surveillance of superficial papillary tumors of the bladder].
    Desrez G; Mandron E; Chatelain C
    Cancer Radiother; 1998 Apr; 2 Suppl 1():27s-30s. PubMed ID: 9749074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between AgNORs, MIB-1 and oncogene expression in male breast carcinoma and papillary superficial bladder neoplasm.
    Pich A; Margaria E; Chiusa L; Bortolin P; Palestro G
    Oncol Rep; 2003; 10(5):1329-35. PubMed ID: 12883702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conservative management of low risk superficial bladder tumors.
    Pruthi RS; Baldwin N; Bhalani V; Wallen EM
    J Urol; 2008 Jan; 179(1):87-90; discussion 90. PubMed ID: 17997444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bladder cancer in Sri Lanka: experience from a tertiary referral center.
    Goonewardena SA; De Silva WA; De Silva MV
    Int J Urol; 2004 Nov; 11(11):969-72. PubMed ID: 15509199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Management of Ta, T1, and in situ bladder carcinoma: what is new?].
    Irani J
    Prog Urol; 2008 May; 18 Suppl 5():S94-8. PubMed ID: 18585634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.